Clinical Trail to Evaluate the Efficacy and Safety of DWJ1451

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 237 participants.

Also called NCT04161001

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 237 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04161001
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04161001. Randomized; double masking; primary purpose treatment. Start 2019-11-20 (anticipated); primary completion 2021-11-20 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Clinical Trail to Evaluate the Efficacy and Safety of DWJ1451
Condition
Hypertension, Dyslipidemia
Intervention (Drug)
Amlodipine/Olmesartan 10/40mg (Combination drug), Ezetimibe/Rosuvastatin 10/20mg(Combination drug)
Intervention (Drug)
Olmesartan 40mg, Ezetimibe/Rosuvastatin 10/20mg(Combination drug)
Intervention (Drug)
Amlodipine/Olmesartan 10/40mg (Combination drug)
Lead sponsor
Daewoong Pharmaceutical Co. LTD. (class: industry)

Record details

Record id
cardio:ct-nct04161001
Content hash
7c18904114c66065f84902b400780c4bcbf705ffabed9419cd8c53997c5680a7